Results 201 to 210 of about 38,436 (213)

GIP Receptor Antagonism Eliminates Paradoxical Growth Hormone Secretion in Some Patients With Acromegaly.

J Clin Endocrinol Metab
Jensen MH, Gasbjerg LS, Skov-Jeppesen K, Jacobsen JCB, Poulsen SS, Zhou C, Jakubauskaite R, Poulsen FR, Bonde C, Albarazi M, Halle B, Christiansen CB, Sanni SJ, Byberg S, Hoe B, Holst JJ, Dela F, Rasmussen AK, Knop FK, Arlien-Søborg MC, Melmed S, Jørgensen JOL, Andersen MS, Hartmann B, Klose MC, Feldt-Rasmussen U, Sparre-Ulrich AH, Rosenkilde MM.   +27 more
europepmc   +1 more source

Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.

J Clin Endocrinol Metab
Gadelha MR, Casagrande A, Strasburger CJ, Bidlingmaier M, Snyder PJ, Guitelman MA, Boguszewski CL, Buchfelder M, Shimon I, Raverot G, Tóth M, Mezősi E, Doknic M, Fan X, Clemmons D, Trainer PJ, Struthers RS, Krasner A, Biller BMK.   +18 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Acromegaly: pathogenesis, diagnosis, and management.

The Lancet Diabetes and Endocrinology, 2022
M. Fleseriu, F. Langlois, D. Lim, E. Varlamov, S. Melmed   +4 more
semanticscholar   +1 more source

Acromegaly in the elderly patients

Endocrine, 2020
M. Ambrosio, I. Gagliardi, S. Chiloiro, A. Ferreira, M. Bondanelli, A. Giampietro, A. Bianchi, L. Marinis, M. Fleseriu, M. Zatelli   +9 more
semanticscholar   +1 more source